Last reviewed · How we verify
Galantamine-CR
Galantamine-CR is a Cholinesterase inhibitor with nicotinic receptor allosteric modulator Small molecule drug developed by Massachusetts General Hospital. It is currently FDA-approved for Mild to moderate Alzheimer's disease, Cognitive decline associated with Alzheimer's disease. Also known as: Razadyne-ER.
Galantamine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking its breakdown, and also acts as an allosteric modulator of nicotinic receptors.
Galantamine-CR is a medication that has been studied for its potential use in treating Alzheimer's Disease, Parkinson's Disease, and Bipolar Disorder. It is a controlled-release formulation of galantamine, a medication that works by inhibiting acetylcholinesterase, an enzyme involved in the breakdown of acetylcholine, a neurotransmitter in the brain.
At a glance
| Generic name | Galantamine-CR |
|---|---|
| Also known as | Razadyne-ER |
| Sponsor | Massachusetts General Hospital |
| Drug class | Cholinesterase inhibitor with nicotinic receptor allosteric modulator |
| Target | Acetylcholinesterase; nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting acetylcholinesterase, galantamine elevates synaptic acetylcholine concentrations, which helps improve cognitive function in neurodegenerative diseases. Additionally, galantamine enhances the function of nicotinic acetylcholine receptors through allosteric modulation, providing a dual mechanism of action. The CR (controlled-release) formulation extends drug exposure to allow once-daily dosing.
Approved indications
- Mild to moderate Alzheimer's disease
- Cognitive decline associated with Alzheimer's disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
- Syncope
- Bradycardia
Key clinical trials
- The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease (PHASE4)
- Galantamine Executive Function in Parkinson's Disease (NA)
- Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Galantamine-CR CI brief — competitive landscape report
- Galantamine-CR updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI
Frequently asked questions about Galantamine-CR
What is Galantamine-CR?
How does Galantamine-CR work?
What is Galantamine-CR used for?
Who makes Galantamine-CR?
Is Galantamine-CR also known as anything else?
What drug class is Galantamine-CR in?
What development phase is Galantamine-CR in?
What are the side effects of Galantamine-CR?
What does Galantamine-CR target?
Related
- Drug class: All Cholinesterase inhibitor with nicotinic receptor allosteric modulator drugs
- Target: All drugs targeting Acetylcholinesterase; nicotinic acetylcholine receptors
- Manufacturer: Massachusetts General Hospital — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Mild to moderate Alzheimer's disease
- Indication: Drugs for Cognitive decline associated with Alzheimer's disease
- Also known as: Razadyne-ER
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing